Scarica l'app Stockscreener
1.98
1.98%
-0.04
Dopo l'orario di chiusura:
1.97
-0.01
-0.51%
Precedente Chiudi:
$2.02
Aprire:
$2.04
Volume 24 ore:
371.43K
Relative Volume:
0.70
Capitalizzazione di mercato:
$259.77M
Reddito:
-
Utile/perdita netta:
$-101.70M
Rapporto P/E:
-1.0442
EPS:
-1.8961
Flusso di cassa netto:
$-84.35M
1 W Prestazione:
-10.41%
1M Prestazione:
-10.41%
6M Prestazione:
+86.79%
1 anno Prestazione:
+138.15%
Intervallo 1D:
$1.96
$2.04
Intervallo di 1 settimana:
$1.96
$2.30
Portata 52W:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Nome
Alx Oncology Holdings Inc
Settore
Industria
Telefono
650-466-7125
Indirizzo
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.98 | 259.77M | 0 | -101.70M | -84.35M | -1.8961 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-06 | Ripresa | UBS | Buy |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-08 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-06 | Iniziato | UBS | Buy |
| 2021-02-10 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Iniziato | Credit Suisse | Outperform |
| 2020-08-11 | Iniziato | Jefferies | Buy |
| 2020-08-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - The Globe and Mail
RLMD Stock Surges 42% in a Week: Here's What You Should Know - sharewise.com
Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation - TipRanks
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - TradingView
ALX Oncology 2025 Annual Report: Evorpacept Clinical Trials, Pipeline Strategy, and CD47 Blockade Advancements - Minichart
ALX Oncology's (ALXO) Buy Rating Reiterated at HC Wainwright - MarketBeat
ALXO: HC Wainwright Reiterates Buy Rating with Price Target at $4.00 | ALXO Stock News - GuruFocus
ALX 2025 10-K: Net loss $101.7M, EPS $(1.90); operating loss $(104.0)M - TradingView
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study - Finviz
Aug Momentum: What is ALX Oncology Holdings Incs book value per share2026 AllTime Highs & Low Risk High Win Rate Picks - baoquankhu1.vn
Alx Oncology Earnings Call Highlights Biomarker Momentum - TipRanks
ALX Oncology initiated with a Buy at UBS - Yahoo Finance
Aug Retail: Does ALX Oncology Holdings Inc stock have upside surprise potentialWatch List & Consistent Income Trade Ideas - baoquankhu1.vn
ALX Oncology (NASDAQ:ALXO) Coverage Initiated by Analysts at UBS Group - MarketBeat
QURE Stock Crashes 32% in a Week: Here's What You Should Know - Finviz
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - Nasdaq
Mirum Completes Enrollment & Screening in Liver Disease Studies - Finviz
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) - The Globe and Mail
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU - The Globe and Mail
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update - MarketBeat
Pharma News: Can Piedmont Office Realty Trust Inc grow without external fundingStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn
ALX Oncology Q4 Earnings Call Highlights - Defense World
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - marketscreener.com
ALXO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO) - Seeking Alpha
Earnings Scheduled For February 27, 2026 - Sahm
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q4 2025 Earnings Call Transcript - Insider Monkey
ALXO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ALXO's Progress in Clinical Trials and Financial Strength - GuruFocus
ALX Oncology (NASDAQ:ALXO) Posts Earnings Results - MarketBeat
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... By GuruFocus - Investing.com Canada
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... - Yahoo Finance
ALX Oncology Q4 2025 Earnings Call Transcript - MarketBeat
ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ALX Oncology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALX Oncology (ALXO) Q4 2025 Earnings Transcript - AOL.com
Earnings call transcript: ALX Oncology Q4 2025 misses EPS forecast, stock dips - Investing.com Canada
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal data ahead - TradingView
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal trial readiness - TradingView
ALXO Prepares for Key Clinical Milestones with Evorpacept and AL - GuruFocus
ALX ONCOLOGY ($ALXO) Releases Q4 2025 Earnings - Quiver Quantitative
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
ALX Oncology (NASDAQ: ALXO) raises $150M and extends cash runway to 2028 - Stock Titan
ALXO: Clinical advances and cost controls drive improved financials and extended cash runway - TradingView
ALXO SEC FilingsAlx Oncology Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look Ahead: ALX Oncology Holdings's Earnings Forecast - Benzinga
ALX Oncology (ALXO) Projected to Post Quarterly Earnings on Friday - Defense World
ALX Oncology Holdings (ALXO) Price Target Increased by 11.11% to 3.40 - Nasdaq
Alx Oncology Holdings Inc Azioni (ALXO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):